Sartorius opens German production facility for bioreactors

Friday, September 14, 2012 12:19 PM

Sartorius, the Germany-based international laboratory and process technology provider, has officially opened its new plant in Guxhagen, Germany, for the manufacture of bioreactors.

After approximately one year of construction and $23.5 million, the new building will now manufacture bioreactors and further production equipment for customers in the biopharmaceutical industry. Covering a total area of nearly 10,000 square feet, the new building complex provides space for a high-tech manufacturing hall and offices for 240 employees. The building owner is Robos GmbH, from which Sartorius has rented the premises in a long-term lease.

"The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment,” said Joachim Kreuzburg, CEO and executive board chairman, Sartorius. “As a result, we are optimally prepared for further expansion, especially for single-use bioreactors.”

Sartorius has moved all operations from its former bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs